Patents by Inventor Roshantha A. Chandraratna

Roshantha A. Chandraratna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity
    Publication number: 20050165095
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR? retinoid receptors.
    Type: Application
    Filed: December 23, 2004
    Publication date: July 28, 2005
    Inventors: Kwok Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha Chandraratna
  • Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors
    Publication number: 20050148590
    Abstract: Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR? agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.
    Type: Application
    Filed: December 17, 2004
    Publication date: July 7, 2005
    Inventors: Kwok Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha Chandraratna
  • Methods of screening for compounds that modulate hormone receptor activity
    Publication number: 20050130232
    Abstract: The present invention provides methods for identifying an effective agent that modulates a biological activity of a nuclear hormone receptor. In a method of the invention, an isolated receptor-containing complex is assayed for an altered modification state as compared to a control modification state. The presence of an altered modification state serves to identify an effective agent that modulates a biological activity of the nuclear hormone receptor.
    Type: Application
    Filed: August 20, 2004
    Publication date: June 16, 2005
    Applicant: Allergan, Inc.
    Inventors: Yi Zhao, Scott Thacher, Jia-Hao Xiao, Jyotirmoy Kusari, Roshantha Chandraratna
  • Methods for modulating FXR receptor activity
    Patent number: 6906057
    Abstract: Methods for modulating the activity of the mammalian FXR receptor. The methods include methods of treating a hyper- or hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds having FXR receptor activity.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: June 14, 2005
    Assignees: Allergan, Inc., City of Hope National Medical Center
    Inventors: Barry M. Forman, Richard L. Beard, Roshantha A. Chandraratna
  • TREATMENT OF TUMORS WITH ACETYLENES DISUBSTITUTED WITH A PHENYL OR HETEROAROMATIC GROUP AND A SUBSTITUTED CHROMANYL, THIOCHROMANYL OR TETRAHYDROQUINOLINYL GROUP IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
    Patent number: 6903121
    Abstract: Compounds of Formula 1 Formula 1 where the symbols have the meaning described in the specification, and particularly the compound of Formula 3 Formula 3 (tazarotene) exhibit synergistic anti-proliferative effect with human recombinant interferon in the treatment of solid tumors and leukemia, particularly breast cancer and acute myeloid leukemia.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: June 7, 2005
    Assignee: Allergan, Inc.
    Inventors: Alissar Nehme, Richard L. Beard, Roshantha A. Chandraratna
  • 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY
    Publication number: 20050096380
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasing triglyceride levels and reducing serum thyroxine levels.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 5, 2005
    Inventors: Richard Beard, Tien Duong, Janet Takeuchi, Ling Li, Kwok Tsang, Xiaoxia Liu, Jayasree Vasudevan, Liming Wang, Santosh Sinha, Haiqing Yuan, Roshantha Chandraratna
  • 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6887896
    Abstract: Compounds of the formula where the variations have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasing triglyceride levels and reducing serum thyroxine levels.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: May 3, 2005
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, Janet A. Takeuchi, Ling Li, Kwok Yin Tsang, Xiaoxia Liu, Jayasree Vasudevan, Liming Wang, Santosh C. Sinha, Haiqing Yuan, Roshantha A. Chandraratna
  • Methods for identifying inhibitors of cytochrome P450RAI
    Patent number: 6855512
    Abstract: A method of identifying a compound which is an inhibitor of the enzyme cytochrome P450RAI is performed by selecting a compound that has retinoid activity in an art recognized assay and includes a benzoic acid, benzoic acid ester, naphthoic acid ester or heteroaryl carboxylic acid or ester moiety, with a partial structure of —A(R2)—(CH2)n—COOR8 where n is 0 and the remaining variables are as described in the specification and claims. Thereafter, a compound having the cytochrome P450RAI inhibitory activity is identified and selected where the compound has the —A(R2)—(CH2)2—COOR8 partial structure wherein the variable n is 1 or 2.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: February 15, 2005
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Liming Wang, Dehua Huang, Roshantha A. Chandraratna
  • O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6855832
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: February 15, 2005
    Assignee: Allergan, Inc.
    Inventors: Vidyasagar Vuligonda, Min Teng, Richard L. Beard, Alan T. Johnson, Yuan Lin, Roshantha A. Chandraratna
  • 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
    Publication number: 20050004213
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.
    Type: Application
    Filed: June 26, 2003
    Publication date: January 6, 2005
    Inventors: Santosh Sinha, Kwok Tsang, Smita Bhat, Roshantha Chandraratna
  • Composition and method for modulating BAR/FXR receptor activity
    Publication number: 20050004165
    Abstract: Methods for modulating the activity of the mammalian BAR/FXR receptor. The methods include methods of treating a hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds able to modulate an activity characteristic of the BAR/FXR receptor. Other methods include a method of treating colon cancer in a mammal comprising administering a compound having a BAR/FXR antagonistic activity.
    Type: Application
    Filed: August 3, 2004
    Publication date: January 6, 2005
    Inventors: Barry Forman, Richard Beard, Isabelle Dussault, Roshantha Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6818775
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: November 16, 2004
    Assignee: Allergan, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
    Publication number: 20040147611
    Abstract: Diabetic mammals are treated with compounds that are significantly more efficacious as agonists of RXR&bgr; retinoid receptors than as agonists of RXR&agr; or RXR&ggr; retinoid receptors. The treatment reduces serum glucose and triglyceride levels of the mammals without the undesirable side effects of reducing serum thyroxine levels and a transient increase in serum triglyceride levels Compounds suitable for use in the methods of treatments of the present invention are selected by testing and identifying compounds of selective or specific efficacy as agonists of RXR&bgr; retinoid receptors in preference over RXR&agr; and/or RXR&ggr; retinoid receptors. Novel compounds used in the methods of the invention have Formula 1 where the variables are defined as disclosed in the specification.
    Type: Application
    Filed: December 17, 2003
    Publication date: July 29, 2004
    Inventors: Yang-Dar Yuan, Richard L. Beard, Roshantha A. Chandraratna
  • 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6759547
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: July 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Haiqing Yuan, Yang-Dar Yuan, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Publication number: 20040127469
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: December 9, 2003
    Publication date: July 1, 2004
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
    Publication number: 20040097733
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: July 2, 2003
    Publication date: May 20, 2004
    Inventors: Richard L. Beard, Thong Vu, Diana F. Colon, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6734193
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: May 11, 2004
    Assignee: Allergan, Inc.
    Inventors: Tien Duong, Richard L. Beard, Roshantha A. Chandraratna
  • Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
    Publication number: 20040077721
    Abstract: vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.
    Type: Application
    Filed: September 5, 2003
    Publication date: April 22, 2004
    Inventors: Yang-Dar Yuan, Jayasree Vasudevan, Scott Thacher, Roshantha A. Chandraratna
  • Methods of treatment during vascular procedures
    Publication number: 20040077710
    Abstract: The invention provides in one embodiment a method for treating vascular trauma. The method can include administering to an individual undergoing vascular trauma an effective amount of a retinoic acid receptor (RAR) antagonist or an RAR inhibitor. The methods can be used to lower serum triglycerides in a patient undergoing an invasive vascular procedure such as vascular surgery.
    Type: Application
    Filed: October 22, 2002
    Publication date: April 22, 2004
    Inventors: Roshantha A. Chandraratna, Yang-Dar Yuan, Tuong P. Dang, Sheng Z. Loh
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6720425
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: April 13, 2004
    Assignee: Allergan, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna